Biotechnology News and Research

RSS

Talecris third quarter net revenue increases 2.8% to $407.0 million

Talecris Biotherapeutics Holdings Corp. today announced its financial results for the three and nine months ended September 30, 2010 and filed its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission (SEC).

29 Oct 2010

Sanofi-aventis to acquire BMP Sunstone

Sanofi-aventis and BMP Sunstone Corporation announced today that they have entered into a definitive agreement under which sanofi-aventis is to acquire all outstanding shares of BMP Sunstone for cash consideration of USD 10 per share, or a total of approximately USD 520.6 million on a fully diluted basis.

29 Oct 2010

ImmunoGen first quarter net loss increases to $12.9 million

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended September 30, 2010 - the first quarter of the Company's 2011 fiscal year (1QFY11).

29 Oct 2010

Metagenics awarded two new patents for hops-derived anti-inflammatory compositions

Metagenics, Inc. has been awarded two new patents for discoveries relating to its research on the anti-inflammatory properties of reduced iso-alpha acids (RIAA) derived from hops. Metagenics is a life sciences company focused on reversing chronic illness and improving health through therapeutic nutrition and lifestyle changes. The discoveries were made by researchers at Metagenics’ wholly-owned biotechnology subsidiary, MetaProteomics® LLC.

28 Oct 2010

Bismuth for bone cement

Organic–inorganic hybrid materials, uniting the advantages of their organic and inorganic parts, are used for a wide variety of applications. However, making a homogeneous composite material is only possible if a solvent can be found in which both components are soluble.

28 Oct 2010

Antigenics third quarter net loss decreases from $10.8 million to $5.9 million

Antigenics Inc. reported today its results for the quarter ended September 30, 2010. The company incurred a net loss attributable to common stockholders of $5.9 million, or $0.06 per share, basic and diluted, for the third quarter of 2010, compared with a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, in the third quarter of 2009.

28 Oct 2010

Omnicare third quarter net sales increases from $1,543.9 million to $1,544.4 million

Omnicare, Inc. one of the nation's leading providers of pharmaceutical care for the elderly, reported today financial results for its third quarter ended September 30, 2010.

28 Oct 2010

BioCryst 2010 third quarter revenue increases from $10.5 million to $12.0 million

BioCryst Pharmaceuticals, Inc. announced financial results for the third quarter and nine months ended September 30, 2010.

28 Oct 2010

QLT expands QLT091001 Phase 1b LCA study to include patients with Retinitis Pigmentosa

QLT Inc. today announced expansion of the Phase 1b clinical proof-of-concept study of QLT091001 in the treatment of Leber Congenital Amaurosis (LCA) to include patients with Retinitis Pigmentosa (RP), a set of hereditary retinal diseases demonstrating clinical features similar to LCA.

28 Oct 2010

United Therapeutics third quarter total revenues increase to $171.0 million

United Therapeutics Corporation today announced its results of operations for the quarter ended September 30, 2010.

28 Oct 2010

Max Planck Innovation licenses new software for metabolite analysis

Max Planck Innovation licenses analysis-technology for metabolites . Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society, has awarded an exclusive license for the analysis software TagFinder to Metabolomic Discoveries GmbH, a service provider in biochemical research.

28 Oct 2010

IntegraGen to open subsidiary in Cambridge, Massachusetts

IntegraGen, Inc., a French biotechnology company dedicated to gene discovery and the development of molecular diagnostic products and services, announced today that it is expanding its operations by opening a U.S. subsidiary headquartered in Cambridge, Massachusetts that will support the company's clinical research initiatives focused on the early identification of children at risk of autism. IntegraGen will open the new office on November 1, 2010.

28 Oct 2010

Evotec grants Jingxin Pharma rights to develop, market EVT 201 insomnia drug candidate in China

Evotec AG today announced that it has entered into a license and collaboration agreement with Zhejiang Jingxin Pharmaceutical Co., Ltd for EVT 201, a novel potential treatment for insomnia. The agreement grants Jingxin Pharma exclusive rights to develop and market the drug candidate in China. In return, Evotec will receive a small upfront payment, together with commercial milestones and significant royalties.

28 Oct 2010

Ipsen reports 8.3% increase in Group sales for first nine months of 2010

Ipsen reported today its sales for the third quarter and the first nine months of 2010.

28 Oct 2010

Endologix announces definitive agreement to acquire Nellix

Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has signed a definitive agreement to acquire Nellix, Inc, a privately-held medical device company that has developed a revolutionary endograft for the treatment of Abdominal Aortic Aneurysms (AAAs).

28 Oct 2010

Vical to present preclinical results of HSV-2 vaccine program at Keystone Symposium

Vical Incorporated today announced that the company's Vice President of Clinical Development, Richard T. Kenney, M.D., is presenting preclinical results from the company's herpes simplex type 2 (HSV-2) vaccine program in a poster session Friday morning at the Keystone Symposium on Immunological Mechanisms of Vaccination (Seattle, October 27 – November 1).

27 Oct 2010

Shionogi receives expanded approval for pediatric use of i.v. peramivir in Japan

BioCryst Pharmaceuticals, Inc. announced that its partner, Shionogi & Co., Ltd. has received approval for an additional indication for use of intravenous (i.v.) peramivir to treat children and infants with influenza in Japan. In January 2010, Shionogi received the world's first approval for i.v. peramivir and launched it under the commercial name RAPIACTA® in Japan.

27 Oct 2010

MedAvante's centralized ratings to be used in Rexahn's Serdaxin Phase 2a study in MDD patients

MedAvante, Inc., the leader in centralized expert evaluation of central nervous system (CNS) disorders, and Rexahn Pharmaceuticals, Inc. a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, announced that Rexahn will use MedAvante 's Remote Centralized Ratings™ in their randomized, double-blind, placebo-controlled Phase 2b clinical study assessing the efficacy of Serdaxin® in patients with major depressive disorder (MDD).

27 Oct 2010

New International malaria research consortium to develop novel classes of antimalarials

Research teams from three academic institutions and two private sector companies on two continents have come together to form the International malaria research consortium for the development of novel classes of antimalarials. This bold initiative will develop novel classes of drugs against malaria, a deadly disease in desperate need of new treatments.

27 Oct 2010

Evotec, Apeiron Biologics enter collaboration

Evotec AG today announced that it has entered into a collaboration with Apeiron Biologics AG, to initially identify small molecule modulators of DREAM (Downstream Regulatory Element Antagonistic Modulator), a novel target involved in perception of various pain mechanisms. Further projects will be evaluated to potentially expand this cooperation in due course.

27 Oct 2010

Biotechnology News and Research

Talecris third quarter net revenue increases 2.8% to $407.0 million

Sanofi-aventis to acquire BMP Sunstone

ImmunoGen first quarter net loss increases to $12.9 million

Metagenics awarded two new patents for hops-derived anti-inflammatory compositions

Bismuth for bone cement

Antigenics third quarter net loss decreases from $10.8 million to $5.9 million

Omnicare third quarter net sales increases from $1,543.9 million to $1,544.4 million

BioCryst 2010 third quarter revenue increases from $10.5 million to $12.0 million

QLT expands QLT091001 Phase 1b LCA study to include patients with Retinitis Pigmentosa

United Therapeutics third quarter total revenues increase to $171.0 million

Max Planck Innovation licenses new software for metabolite analysis

IntegraGen to open subsidiary in Cambridge, Massachusetts

Evotec grants Jingxin Pharma rights to develop, market EVT 201 insomnia drug candidate in China

Ipsen reports 8.3% increase in Group sales for first nine months of 2010

Endologix announces definitive agreement to acquire Nellix

Vical to present preclinical results of HSV-2 vaccine program at Keystone Symposium

Shionogi receives expanded approval for pediatric use of i.v. peramivir in Japan

MedAvante's centralized ratings to be used in Rexahn's Serdaxin Phase 2a study in MDD patients

New International malaria research consortium to develop novel classes of antimalarials

Evotec, Apeiron Biologics enter collaboration

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News